Professor Trent Woodruff
Professor

Trent Woodruff

Email: 
Phone: 
+61 7 336 52924

Background

Dr Woodruff is a Professor of Pharmacology who leads a research team aiming to find new therapeutic treatments for neurodegenerative disorders. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Prof Woodruff’s specific research revolves around the innate immune system in the brain, and the role of neuroinflammation in propagating disease. A key focus of his current work is testing new drugs developed at the University of Queensland in models of motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson's disease, as well as maintaining an active interest in acute inflammatory disorders including sepsis and ischemia-reperfusion injuries. Using a series of potent and orally active complement C5a and NLRP3 inflammasome inhibitors developed at UQ, Prof Woodruff's team has demonstrated the therapeutic potential of targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of these neurodegenerative diseases. His team has recently shown that in addition to their roles in neurodegeneration, innate immune factors also play essential roles in stem and neuronal cell development during embryogenesis, revealing the widespread physiological and pathological roles of this evolutionarily ancient immune system.

Availability

Professor Trent Woodruff is:
Available for supervision
Media expert

Fields of research

Immunology Neurosciences Pharmacology and pharmaceutical sciences

Qualifications

  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Neurodegenerative disease

    Studying new treatments to halt disease progression

  • Parkinson's disease

    Studying new treatments to halt disease progression

  • Motor neuron disease

    Studying new treatments to halt disease progression

Search Professor Trent Woodruff’s works on UQ eSpace

316 works between 2000 and 2025
All (316) Journal Article (235) Book Chapter (10) Conference Publication (70) Other Outputs (1)

241 - 260 of 316 works

2012

Journal Article

Complement activation in the injured central nervous system: Another dual-edged sword?

Brennan, Faith H., Anderson, Aileen J., Taylor, Stephen M., Woodruff, Trent M. and Ruitenberg, Marc J. (2012). Complement activation in the injured central nervous system: Another dual-edged sword?. Journal of Neuroinflammation, 9 (1) 137, 137. doi: 10.1186/1742-2094-9-137

Complement activation in the injured central nervous system: Another dual-edged sword?

2012

Journal Article

Complement C5a regulates prolabor mediators in human placenta

Lappas, Martha, Woodruff, Trent M., Taylor, Stephen M. and Permezel, Michael (2012). Complement C5a regulates prolabor mediators in human placenta. Biology of Reproduction, 86 (6) 190, 190.1-190.9. doi: 10.1095/biolreprod.111.098475

Complement C5a regulates prolabor mediators in human placenta

2012

Journal Article

De novo peptide design with C3a receptor agonist and antagonist activities: Theoretical predictions and experimental validation

Bellows-Peterson, Meghan L., Fung, Ho Ki, Floudas, Christodoulos A., Kieslich, Chris A., Zhang, Li, Morikis, Dimitrios, Wareham, Kathryn J., Monk, Peter N., Hawksworth, Owen A. and Woodruff, Trent M. (2012). De novo peptide design with C3a receptor agonist and antagonist activities: Theoretical predictions and experimental validation. Journal of Medicinal Chemistry, 55 (9), 4159-4168. doi: 10.1021/jm201609k

De novo peptide design with C3a receptor agonist and antagonist activities: Theoretical predictions and experimental validation

2012

Conference Publication

Antagonizing C5aR reduces T Cell- IL-10-dependent colitis in pre-clinical models

Jain, Umang, Woodruff, Trent and Stadnyk, Andrew (2012). Antagonizing C5aR reduces T Cell- IL-10-dependent colitis in pre-clinical models. 2012 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s National Clinical & Research Conference, Hollywood, Fl, United States, 13-15 December 2012. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1002/ibd.23058

Antagonizing C5aR reduces T Cell- IL-10-dependent colitis in pre-clinical models

2012

Conference Publication

Deficiency of the complement anaphylatoxin receptor C3aR on leukocytes worsens the outcome from spinal cord injury by promoting neutrophilia

Brennan, Faith H., Blomster, Linda V., Costantini, Alexander M., Taylor, Stephen M., Woodruff, Trent M. and Ruitenberg, Marc J. (2012). Deficiency of the complement anaphylatoxin receptor C3aR on leukocytes worsens the outcome from spinal cord injury by promoting neutrophilia. 11th International Congress of Neuroimmunology (ISNI), Boston MA., United States, 4-8 November 2012. Amsterdam, The Netherlands: Elsevier.

Deficiency of the complement anaphylatoxin receptor C3aR on leukocytes worsens the outcome from spinal cord injury by promoting neutrophilia

2012

Conference Publication

The C3a receptor mediates protection from intestinal ischemia reperfusion injuries by impairing neutrophil mobilization

Woodruff, Trent M., Wu, Mike C. L., Brennan, Faith H., Wetsel, Rick A., Ruitenberg, Marc J. and Taylor, Stephen M. (2012). The C3a receptor mediates protection from intestinal ischemia reperfusion injuries by impairing neutrophil mobilization. 24th International Complement Workshop (ICW), Chania, Crete, Greece, 10-15 October 2012. Jena, Germany: Urban und Fischer Verlag. doi: 10.1016/j.imbio.2012.08.229

The C3a receptor mediates protection from intestinal ischemia reperfusion injuries by impairing neutrophil mobilization

2012

Book Chapter

Innate immunity in ALS

Lee, John D., Lee, Jia Y., Taylor, Stephen M., Noakes, Peter G. and Woodruff, Trent M. (2012). Innate immunity in ALS. Amyotrophic lateral sclerosis. (pp. 393-412) edited by Martin H. Maurer. Croatia: InTech - Open Access Publisher. doi: 10.5772/30341

Innate immunity in ALS

2012

Conference Publication

De novo protein design of agonists and antagonists of C5a receptors

Monkl, Peter N., Bellows-Peterson, Meghan L., Smadbeck, James, Floudas, Christodoulos A., Kieslich, Christopher A., Morikis, Dimitrios and Woodruff, Trent M. (2012). De novo protein design of agonists and antagonists of C5a receptors. 24th International Complement Workshop (ICW), Chania, Crete, Greece, 10-15 October 2012. Jena, Germany: Urban und Fischer Verlag. doi: 10.1016/j.imbio.2012.08.097

De novo protein design of agonists and antagonists of C5a receptors

2012

Conference Publication

Expression of complement factors and functional C5a receptors in human embryonic stem cells, and induced pluripotent stem cells

Hawksworth, Owen A., Coulthard, Liam G., Taylor, Stephen M., Wolvetang, Ernst J. and Woodruff, Trent M. (2012). Expression of complement factors and functional C5a receptors in human embryonic stem cells, and induced pluripotent stem cells. 24th International Complement Workshop (ICW), Chania, Crete, Greece, 10-15 October 2012. Jena, Germany: Urban und Fischer Verlag. doi: 10.1016/j.imbio.2012.08.116

Expression of complement factors and functional C5a receptors in human embryonic stem cells, and induced pluripotent stem cells

2012

Conference Publication

The complement receptors CD88, C5L2 and C3AR mediate inflammatory injury following transient cerebral ischemia

Pavlovski, D., Thundyil, J., Taylor, S. M., Arumugam, T., V and Woodruff, T. M. (2012). The complement receptors CD88, C5L2 and C3AR mediate inflammatory injury following transient cerebral ischemia. Stroke 2012 Conference - A combined event of the Stroke Society of Australasia 2012 Annual Scientific Meeting and the 8th Smart Strokes Australasian Nursing and Allied Health Stroke Conference, Sydney NSW Australia, 29-31 August 2012. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia.

The complement receptors CD88, C5L2 and C3AR mediate inflammatory injury following transient cerebral ischemia

2011

Journal Article

Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats

Iyer, Abishek, Woodruff, Trent M., Wu, Mike C. L., Stylianou, Con, Reid, Robert C., Fairlie, David P., Taylor, Stephen M. and Brown, Lindsay (2011). Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. Journal of Cardiovascular Pharmacology, 58 (5), 479-486. doi: 10.1097/FJC.0b013e31822a7a09

Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats

2011

Journal Article

Inhibiting the C5-C5a receptor axis

Woodruff, Trent M., Nandakumar, Kutty S. and Tedesco, Francesco (2011). Inhibiting the C5-C5a receptor axis. Molecular Immunology, 48 (14), 1631-1642. doi: 10.1016/j.molimm.2011.04.014

Inhibiting the C5-C5a receptor axis

2011

Journal Article

Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats

Breivik, T., Gundersen, Y., Gjermo, P., Taylor, S. M., Woodruff, T. M. and Opstad, P. K. (2011). Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. Journal of Periodontal Research, 46 (6), 643-647. doi: 10.1111/j.1600-0765.2011.01383.x

Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats

2011

Journal Article

Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice

Manthey, Helga D., Thomas, Anita C., Shiels, Ian A., Zernecke, Alma, Woodruff, Trent M., Rolfe, Barbara and Taylor, Stephen M. (2011). Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice. FASEB Journal, 25 (7), 2447-2455. doi: 10.1096/fj.10-174284

Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice

2011

Journal Article

Pathophysiology, treatment, and animal and cellular models of human ischemic stroke

Woodruff, Trent M., Thundyil, John, Tang, Sung Chun, Sobey, Christopher G., Taylor, Stephen M. and Arumugam, Thiruma V. (2011). Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Molecular Neurodegeneration, 6 (1) 11, 1-19. doi: 10.1186/1750-1326-6-11

Pathophysiology, treatment, and animal and cellular models of human ischemic stroke

2011

Journal Article

Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors

Hezmee, Mohd Noor Mohd, Kyaw-Tanner, Myat, Lee, Jia Yu Peppermint, Shiels, Ian A., Rolfe, Barbara, Woodruff, Trent and Mills, Paul C. (2011). Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors. Veterinary Immunology and Immunopathology, 139 (1), 50-56. doi: 10.1016/j.vetimm.2010.08.005

Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors

2011

Journal Article

Comparative efficacy of a secretory phospholipase A(2) inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis

Coulthard, Liam G., Costello, Jaclyn, Robinson, Brent, Shiels, Ian A., Taylor, Stephen M. and Woodruff, Ttrent M. (2011). Comparative efficacy of a secretory phospholipase A(2) inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis. Arthritis Research & Therapy, 13 (2) R42, R42-1-R42-10. doi: 10.1186/ar3278

Comparative efficacy of a secretory phospholipase A(2) inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis

2010

Journal Article

Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death

Thundyil, John, Tang, Sung-Chun, Okun, Eitan, Shah, Kausik, Karamyan, Vardan T., Li , Yu-I, Woodruff, Trent M., Taylor, Stephen M., Jo, Dong-Gyu, Mattson, Mark P and Arumugam, Thiruma V. (2010). Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. Experimental and Translational Stroke Medicine, 2 (1) 15, 15-1-15-8. doi: 10.1186/2040-7378-2-15

Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death

2010

Journal Article

The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells

Nishiura, Hiroshi, Tokita, Kazutaka, Li, Ying, Harada, Koichi, Woodruff, Trent W., Taylor, Stephen M., Nsiama, Tienabe K., Nishino, Norikazu and Yamamoto, Tetsuro (2010). The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells. Apoptosis, 15 (8), 966-981. doi: 10.1007/s10495-010-0511-y

The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells

2010

Journal Article

The role of the complement system and the activation fragment C5a in the central nervous system

Woodruff, T. M., Ager, R. R., Tenner, A. J., Noakes, P. G. and Taylor, S. M. (2010). The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Medecine, 12 (2), 179-192. doi: 10.1007/s12017-009-8085-y

The role of the complement system and the activation fragment C5a in the central nervous system

Current funding

  • 2024 - 2027
    Preclinical development of complement C5a receptor 2 modulators for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2024 - 2025
    Examining the efficacy of monepantel in the 6-OHDA model of Parkinson's disease
    PharmAust Limited
    Open grant
  • 2024 - 2025
    Investigating the pharmacological activity of monepantel on autophagy in the NSC-34 motor neuron cell line
    PharmAust Limited
    Open grant
  • 2024 - 2026
    Developing novel peptide tracers for improving immunotherapy outcomes
    NHMRC Development Grant
    Open grant
  • 2022 - 2025
    Therapeutic Inhibition of Neutrophil Activity as a Disease-Modifying Treatment for Amyotrophic Lateral Sclerosis
    United States Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program
    Open grant
  • 2022 - 2025
    Making peptides orally bioavailable
    ARC Discovery Projects
    Open grant
  • 2022 - 2026
    Developing new therapies targeting innate immune mediated inflammation in neurodegenerative disease
    NHMRC Investigator Grants
    Open grant

Past funding

  • 2023 - 2024
    Therapeutic potential of targeting one of the core players of inflammation (Inflammasome) in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    C9orf72 dipeptide-mediated activation of microglia as a therapeutic target for MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    Inhibiting complement C5a receptors to improve heart function in type 2 diabetes (DARP Grant administered by Monash University
    Monash University
    Open grant
  • 2022 - 2024
    Profiling monocytes in MND to assess disease progression and heterogeneity
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2023
    An integrated analytical network for protein characterisation
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2022 - 2024
    Developing FXIIa inhibitors as next-generation anticoagulants
    NHMRC Development Grant
    Open grant
  • 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND
    Motor Neurone Disease Research Institute of Australia Inc Linda Rynalski Bridge Funding Grant
    Open grant
  • 2021 - 2023
    Complement C5aR1: A novel therapeutic target for brain cancer
    Brain Cancer Innovation Project Grants
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2021
    Inflammatory biomarkers in 6-OHDA mouse model of Parkinson's disease
    UniQuest Pty Ltd
    Open grant
  • 2020 - 2024
    Preclinical development of centrally active complement C3a receptor modulators as disease-modifying drugs for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2020 - 2022
    Investigating the PROfile of complement activation in relation to Vasospasm, delayed cerebral Ischaemia and aneurysmal Subarachnoid haemorrhage Outcomes (ProcVISO Study) (administered by RBWH)
    Metro North Hospital and Health Service
    Open grant
  • 2020 - 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2022
    Eph receptor blockade to prevent and repair endothelial damage in systemic inflammation
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019
    A versatile accurate mass, high resolution QTOF mass spectrometer for chemistry and proteomic applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Advanced Brightfield and Fluorescent High Speed and Throughput Slide Scanner for biological, medical, materials science, and agricultural applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2023
    Harnessing the Innate Immune System to Target Cancer: A Novel Immunotherapeutic Strategy for Solid Tumours
    NHMRC Development Grant
    Open grant
  • 2019 - 2020
    Role of NLRP3 inflammasome activation in the prognosis of secondary progressive multiple sclerosis
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    Understanding the mechanism of action for intravenous immunoglobulin (IVIG) therapy in spinal cord injury
    NHMRC Project Grant
    Open grant
  • 2018 - 2019
    Targeting peripheral inflammatory pathology in Parkinson's disease using repurposed drugs
    Wesley Medical Research Ltd
    Open grant
  • 2018 - 2019
    Therapeutic inhibition of the terminal complement pathway as a disease-modifying treatment for motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic testing of the clinical candidate drug PMX205 in a TDP43-based model of MND and its mechanism
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2020
    Therapeutic potential of inhibiting Eph/ephrin signalling to repair the vascular endothelium in septic shock
    NHMRC Project Grant
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    A potential role for C5a antagonism in the medical management of feline hypertrophic cardiornyopathy
    Peter & Mary Ellen Stone Memorial Fund
    Open grant
  • 2017 - 2019
    Defining inflammatory biomarkers in motor neuron disease patients to assist in clinical trial efficiency of the C5aR antagonist PMX205
    Wesley Medical Research Ltd
    Open grant
  • 2017 - 2020
    New Treatments for Brain Disease
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2023
    The Queensland Drug Repurposing Initiative
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2019
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in children with severe sepsis?
    Financial Markets Foundation for Children
    Open grant
  • 2017 - 2018
    Therapeutic inhibition of HMGB1 to slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2017 - 2021
    Preclinical Development of Complement C5aR Antagonists for the Treatment of Motor Neuron Disease
    NHMRC Development Grant
    Open grant
  • 2016 - 2018
    Pharmacological Targeting of Proinflammatory Kinase Signalling in Parkinson's disease
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2016 - 2020
    Blocking inflammasome-induced neuroinflammation in PD with a potent, orally available small molecule
    The Michael J Fox Foundation Therapeutic Pipeline Program
    Open grant
  • 2016 - 2018
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in patients with septic shock?
    Bayer Pharma AG
    Open grant
  • 2016 - 2017
    Development of complement C5aR1 antagonists for the treatment of motor neuron disease
    UQ Collaboration and Industry Engagement Fund - FirstLink
    Open grant
  • 2016 - 2017
    Exploiting the opposing actions of complement receptors C3aR and C5aR1 in the treatment of MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016 - 2020
    Therapeutic targeting of neuroinflammation to slow the progression of neurodegenerative disease
    NHMRC Career Development Fellowship
    Open grant
  • 2016
    Exosome and Bio/Nanoparticle Characterisation Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016 - 2018
    Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Pharmacological targeting of the NLRP3 inflammasome in pre-clinical models of Parkinson's disease using a potent orally active inhibitor
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2015 - 2017
    Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2020
    Determining the contribution of peripheral immune complement signalling in the progression of motor neuron disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Inhibitors of NLRP3 activation for treatment of inflammatory CNS diseases
    NHMRC Project Grant
    Open grant
  • 2015
    Therapeutic targeting of inflammation in Parkinson's disease
    RL Cooper Medical Research Foundation Limited
    Open grant
  • 2015 - 2016
    Therapeutic targeting of the NLRP3 inflammasome using a potent and orally active inhibitor in experimental MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Development of a rapid ex vivo screening assay for immunotoxicity of nanoparticles
    UQ Collaboration and Industry Engagement Fund - Seed Research Grant
    Open grant
  • 2014
    Innate immune complement signalling in peripheral immune cells during the progression of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    Establishment of an Integrated Facility for Single Cell Analysis
    UQ Major Equipment and Infrastructure
    Open grant
  • 2012 - 2016
    Investigating the Role of the Innate Immune Complement System in the Abnormal Development of the Central Nervous System
    ARC Future Fellowships
    Open grant
  • 2012 - 2014
    Contribution of Complement C5a to Neuronal Cell Death during Ischemic Stroke
    NHMRC Project Grant
    Open grant
  • 2012
    Establishment of Integrated Small Animal Metabolic and Physiology Assessment Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    Microdialysis to monitor fluid shifts and predict organ failure in the systemic inflammatory response syndrome
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2011
    A Multi-Channel Fluorescence Plate Reader for Studying Receptor-Ligand Interactions
    NHMRC Equipment Grant
    Open grant
  • 2011
    Building UQ's analytical capacity in biomedical sciences
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Molecular Stereology Facility Upgrade
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Real time regional tissue analysis suite
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    The role of the innate immune system during the progression of motor neuron disease; the search for new therapeutic targets
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011 - 2013
    Therapeutic Targeting of Complement C5a Receptors in Huntington's Disease
    NHMRC Project Grant
    Open grant
  • 2010 - 2012
    Therapeutic modulation of the innate immune complement system as a new and adjunct therapy to treat a wide variety of cancers
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010 - 2012
    Complement activation in experimental epilepsy: role of C5a receptors
    NHMRC Project Grant
    Open grant
  • 2010
    In Situ Hybridization Suite for Biomedical Science Researchers
    NHMRC Equipment Grant
    Open grant
  • 2010 - 2011
    Notch-1 contributes to neuronal cell death and glial inflammation by modulating NFkappaB activity in ischaemic stroke
    National Heart Foundation of Australia
    Open grant
  • 2009 - 2011
    Characterizing novel therapeutic interventions in a new model of focal retinopathy
    NHMRC Project Grant
    Open grant
  • 2009 - 2013
    Complement C5a Receptors , Placental Inflammation and Reproductive Impairment.
    NHMRC Project Grant
    Open grant
  • 2009
    Liquid Scintillation Spectroscopy Facility
    UQ School/Centre Co-Funding
    Open grant
  • 2009
    Role of Complements Anaphylatoxin Receptors in Experimental Stroke
    UQ Early Career Researcher
    Open grant
  • 2008 - 2010
    Characterisation of the effect of C5a receptor antagonists against the C5a-like receptor 2 (C5L2)
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2008 - 2010
    Establishment of therapeutically relevant animal models and markers for Crohn's Disease
    ARC Linkage Projects
    Open grant
  • 2008 - 2012
    NHMRC Career Development Award (Biomedical - Level 1): The role of the complement system in neurodegeneration and the therapeutic potential of complement inhibition
    NHMRC Career Development Award
    Open grant
  • 2008
    Role of the complement system in the healthy and diseased central nervous system
    ARC Discovery Projects
    Open grant
  • 2007 - 2008
    Scientific Visit - Protective actions of novel anti-inflammatory agents in neurotoxin-damaged neuronal cultures mimicking Parkinson's disease
    Australian Academy of Science
    Open grant
  • 2005
    The effectiveness of C5a receptor antagonists in the treatment of motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant

Availability

Professor Trent Woodruff is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Role of immune and inflammatory pathways in the progression of neurodegenerative disease

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Professor Trent Woodruff directly for media enquiries about:

  • Drug Development
  • Huntington's disease
  • motor neuron disese
  • Neurodegenerative disease
  • Parkinson's disease

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au